Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 38Pancreatic Neoplasms 16Colonic Neoplasms 12Rectal Neoplasms 11Stomach Neoplasms 9Neoplasms 9Neuroblastoma 8Small Cell Lung Carcinoma 7Rhabdomyosarcoma 7Neoplasm Metastasis 7Glioblastoma 7Sarcoma, Ewing 6Gastrointestinal Neoplasms 6Central Nervous System Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Glioma 5Sarcoma 4Brain Neoplasms 4Medulloblastoma 3Intestinal Neoplasms 3Gliosarcoma 3Gastrointestinal Diseases 3Esophageal Neoplasms 3Digestive System Neoplasms 3Digestive System Diseases 3Astrocytoma 3Advanced Solid Tumors 3Recurrence 2Rectal Diseases 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2

Interventions

regorafenib 1napabucasin 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Gastrointestinal Cancer × Irinotecan × Clear all
NCT02024607 2023-11-15

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
495 enrolled 18 charts
Gastrointestinal

Advanced Gastrointestinal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡